Albumin Paclitaxel
Phase 3Small molecule
Albumin Paclitaxel is one of 309 small molecule programs targeting Pancreatic Neoplasm. It is currently in Phase 3.
13
Indications
32
Total Trials
19
Active Trials
308
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Albumin Paclitaxel
CChipscreen Biosciences, Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
N/ANot yet recruiting
Efficacy and Safety
NCT06603974
Phase 2/3Recruiting
Pathological Response
NCT05125055
Phase 2Active, not recruiting
Lung Cancer
NCT04836728
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer3 trials
Esophageal Squamous Cell Carcinoma2 trials
Breast Cancer2 trials
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04681911·71 enrolled
Esophageal Carcinoma2 trials
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Unknown status·—·Phase 1/2·NCT05777707·89 enrolled
Gastric Cancer2 trials
A Randomized Controlled Study of 2nd-line Treatment of Advanced G/GEJ Adenocarcinoma With Fruquintinib and Albumin-paclitaxel in Combination With or Without PD-1 Antibody in Patients Who Have Failed Treatment With PD-1 Antibody
Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences··NCT06417892·60 enrolled
19 more indications
Pancreatic Ductal Adenocarcinoma2 trials
Head and Neck Squamous Cell Carcinoma2 trials
A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma
Active, not recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06081673·72 enrolled
Brain Metastases1 trial
Oral Squamous Cell Carcinoma1 trial
Pathological Response1 trial
Triple-Negative Breast Cancer1 trial
Neoadjuvant Therapy1 trial
Neoadjuvant Treatment1 trial
Patients With Advanced Solid Tumors1 trial
Mucosal Melanoma1 trial
Nasopharyngeal Carcinoma1 trial
Paclitaxel1 trial
Pancreatic Neoplasm1 trial
Lung Cancer1 trial
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04836728·156 enrolled
First-line Treatment1 trial
Cervical Cancer1 trial
Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04884906·40 enrolled
Chemotherapy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Albumin Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CChipscreen Biosciences, Ltd.